FibroGen, Inc. (FGEN)

US — Healthcare Sector
Peers: AKBA  RARE  ERAS  CABA  REPL  BPMC  ATRA  MGNX  KPTI 

Automate Your Wheel Strategy on FGEN

With Tiblio's Option Bot, you can configure your own wheel strategy including FGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FGEN
  • Rev/Share -0.2332
  • Book/Share -1.7328
  • PB -3.0298
  • Debt/Equity 0.0
  • CurrentRatio 2.0238
  • ROIC -1.4591

 

  • MktCap 21000000.0
  • FreeCF/Share -0.7552
  • PFCF -0.2754
  • PE -52.9638
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.048

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
FGEN
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence R&D Duchenne Muscular Dystrophy. The …

Read More
image for news Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
FGEN
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Read More
image for news FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

About FibroGen, Inc. (FGEN)

  • IPO Date 2014-11-14
  • Website https://www.fibrogen.com
  • Industry Biotechnology
  • CEO Thane Wettig
  • Employees 225
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.